Home GPCR & G Protein FPR

FPR

Other GPCR & G Protein Related Inhibitors

Hedgehog/Smoothened PKA CGRP Receptor Endothelin Receptor S1P Receptor Cannabinoid Receptor SGLT Opioid Receptor GPR CCR

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S9818 WRW4 WRW4 is a specific formyl peptide receptor-like 1 (FPRL1) antagonist that inhibits WKYMVm binding to FPRL1 with IC50 of 0.23 μM. This compound is a selective antagonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX).
Exp Mol Med, 2025, 57(9):2067-2082
Neurosci Res, 2025, 218:104932
In Vitro Cell Dev Biol Anim, 2025, 10.1007/s11626-024-01008-9
S0547 HCH6-1 HCH6-1 is a selective competitive antagonist of formyl peptide receptor 1 (FPR1) and has protective effects against acute lung injury (ALI). This compound may have potential as a new therapeutic agent for treating FPR1-involved inflammatory lung diseases.
Respir Res, 2025, 26(1):308
Signal Transduct Target Ther, 2024, 9(1):193.
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes.
Materials Today Bio, 2025, 101630
Mater Today Bio, 2025, 31:101630
E7571 FPR Agonist 43 FPR Agonist 43 (Compound 43) is a potent synthetic dual agonist of FPR1 and FPR2/ALX receptors that promotes the resolution of inflammation and tissue repair by inducing receptor cross-desensitization to limit neutrophil migration and reduce pro-inflammatory cytokines like TNF-α.
E4628 BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. This compound therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.
E7684 Ac2-26 Ac2-26 is an annexin A1 (lipocortin 1)-mimetic peptide that inhibits leukocyte extravasation by reducing neutrophil adhesion and emigration, promotes neutrophil detachment from activated mesenteric endothelium, and accelerates epithelial wound repair in models of induced colonic injury in mice. It also decreases AnxA1 expression while inhibiting NF-κB and MAPK pathway activation in injured lung tissue, likely via the activation of the formyl peptide receptor (FPR) signaling pathway.